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SHORT COMMUNICATION
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It is usually the metabolites of environmental carcinogens
that initiate a cancer (Miller & Miller, 1983), and if the
metabolism were subject to genetically determined poly-
morphism, there could be variation between smokers in their
susceptibility to smoking-related lung cancer. We report a
case-control study using the drug debrisoquine as a potential
marker of such genetically determined susceptibility to lung
cancer.
Debrisoquine has only one major metabolite, 4-hydroxy
debrisoquine (Idle et al., 1979), and the extent of 4-
hydroxylation before excretion is controlled by a single gene
and segregates into two distinct phenotypes - autosomal
recessive poor metabolisers (about 9% of white populations,
hydroxylating only 1-2% of a 10mg dose of debrisoquine)
and homozygous and heterozygous dominant extensive meta-
bolisers (hydroxylating 10-99%) (Evans et al., 1980; Steiner
et al., 1985). Unchanged and 4-hydroxy debrisoquine can be
measured easily and with high reproducibility (r=0.88) in
urine (Evans et al., 1980). The oxidative metabolism of over
20 drugs and other chemicals is known to be controlled by
the same single gene locus as debrisoquine, and exhibits the
same polymorphism (Sloan et al., 1978; Eichelbaum, 1984).
There is no specific basis for a prior hypothesis, but the
metabolism of a carcinogen in tobacco smoke could be
subject to the same polymorphism.
Ayesh et al. (1984) reported a case-control study showing
an association between lung cancer and extensive metabolism
of debrisoquine. However D.S. Davies et al. (personal
communication) have found no such association while Roots
et al. (1988) considered the association to be at best weak or
confined to certain histological types. This prompted us to
report the present study to help resolve the uncertainty. It
was performed in 1982 as a preliminary study to the larger
study of Ayesh et al., but different investigators supervised
the tests and measured metabolic ratio, and the subjects were
recruited from different sources.
We recruited consecutive caucasian inpatients with newly
diagnosed lung cancer from a London hospital. Cigarette
smoking histories were documented as accurately as possible
and recorded in pack-years (one-twentieth the average daily
number of cigarettes smoked multiplied by the number of
years of smoking). Subjects whose total cigarette
consumption was less than 10 pack years, or who had given
up smoking more than five years previously were excluded.
We also excluded patients with elevated serum bilirubin
(>25mmoll-1), and those who were taking drugs known to
induce oxidising enzymes (e.g. barbiturates) or to compete
with debrisoquine for oxidation (Sloan et al., 1978;
Eichelbaum, 1984). A total of 104 cases were included. The
histological types were squamous cell (38 cases), large cell
(22), small cell (31), adenocarcinoma (11) and
undifferentiated (2), diagnosed histologically (92) or
cytologically (12). The 104 control subjects were residents of
three homes for ex-servicemen (70), inpatients with various
non-malignant diseases (22) and hospital employees (12).
They were matched to the cases by sex (76 men, 28 women),
age (mean 62.6 years+s.d. 9.2 in cases, 61.4+ 10.1 in controls)
and cigarette consumption (54.5 pack-years+32.0 in cases,
54.0 +33.1 in controls).
Cases and controls took a single 10mg debrisoquine tablet
at 7 a.m. and made an 8 h urine collection, from which
aliquots were stored at -20°C to await analysis by electron-
capture gas-chromatography (Idle et al., 1979). The ratio of
unchanged to 4-hydroxy debrisoquine concentration, the
metabolic ratio, was used to assign phenotype, the antimode
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Figure 1 Metabolic ratio for debrisoquine in 104 lung cancer
cases and 104 controls. The effect in the cases of certain drugs
on metabolic ratio is shown: Distalgesic (irregular shading),
cytotoxic drugs (diagonal lines), Moduretic (horizontal lines),
diazepam (stippled).
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Table I Metabolic ratios among extensive metabolisers
log1o metabolic Comparison with
ratio remaining cases'
n (mean (s.d.)) (Z)
Cases taking:
Distalgesic 25 +0.47 (0.32) 9.2 (P<0.001)
cytotoxic drugs 5 +0.35 (0.23) 5.1 (P<0.001)
Moduretic 2 +0.65 (0.14) 8.1 (P<0.001)
diazepam 5 +0.03 (0.19) 2.1 (P=0.03)
Remaining cases 65 -0.30 (0.34)
Controls 95 -0.14 (0.43) -2.5 (P=0.01)
distinguishing poor from extensive metabolisers occurring at
a metabolic ratio of 12.6 (Evans et al., 1980).
Results are shown in Figure 1. Two of 104 (1.9%) lung
cancer cases and nine of 104 (8.7%) controls were poor
metabolisers: P (one-tailed) =0.03 (Fisher's exact test).
Statistical significance is greater if the larger series of 258
normal subjects of Evans et al. (1980) is used as controls
(2P=0.02). Among extensive metabolisers the distribution of
metabolic ratio in controls was approximately log-normal
and similar to that in studies of normal volunteers (Evans et
al., 1980; Steiner et al., 1985). In the cases it was skewed to
the right by the effect of certain drugs, as shown in Figure 1.
Metabolic ratios were statistically significantly higher in
patients taking four drugs, namely Distalgesic, cytotoxics
Moduretic and diazepam, than in the remaining cases
(Table I). No drugs were associated with a lower metabolic
ratio. In the 65 extensive metaboliser cases not taking any of
the above four drugs, mean metabolic ratio was statistically
significantly lower than in the 95 extensive metaboliser
controls (none of whom were taking any of the four drugs)
(Table I).
This study confirms that fewer lung cancer cases than
controls were poor metabolisers of debrisoquine
(1.9% vs 8.7%). The results of Ayesh et al. (1984) were very
similar; four of 245 (1.6%) cases and 21 of 234 (9.0%)
controls were poor metabolisers (P<0.01). Poor metabolisers
thus have one-fifth the risk of smoking-related lung cancer
of extensive metabolisers. Among extensive metabolisers one
might expect more lung cancer cases than controls to be
homozygous, and in keeping with this metabolic ratio was
lower on average (i.e. more debrisoquine was hydroxylated)
in lung cancer cases (excluding those taking certain drugs)
than in controls.
No apparent sources of bias can explain the association of
extensive debrisoquine hydroxylation with lung cancer.
Those drugs known to affect metabolic ratio increase it, the
bias thus operating against the result of fewer poor
metabolisers among lung cancer cases. A biological effect of
the cancer is a possible explanation, but in animal studies
mono-oxygenase activities appear depressed by the presence
of cancer (Rosso et al., 1971), such a bias again operating
against the result. Steiner et al. (1985) found that smoking
and various other environmental factors such as alcohol,
body weight and exercise that might differ between cases and
controls did not demonstrably influence metabolic ratio,
apart from a modest association with coffee intake.
Moreover, as discussed by Nebert (1981), the metabolic
effects of environmental factors are generally not powerful
enough to mimic genetic effects of the magnitude observed
here (extensive metabolisers hydroxylating about 50 times as
much debrisoquine as poor metabolisers on average). We
conclude that the association observed in two studies, in the
absence of any apparent source of bias, constitutes evidence
for genetic predisposition to smoking-related lung cancer.
The association may be interpreted directly as a shared
enzymatic pathway with an unspecified carcinogen, or
indirectly as linkage disequilibrium, the gene locus
regulating debrisoquine hydroxylation being closely
associated on the same chromosome with a locus that
independently affects lung cancer risk.
Further progress in elucidating metabolic predisposition to
cancer is likely to be dominated by recombinant DNA
technology, which is free from the bias associated with
metabolic studies. The gene responsible for extensive debriso-
quine hydroxylation is a structural gene, its complementary
DNA has been cloned and sequenced, and three different
mutant genes have been identified that give rise to
incorrectly spliced messenger RNAs unable to yield an
immunodetectable protein in the liver (Gonzalez et al., 1988).
Unfortunately these three mutant genes can account for only
about half of all poor metabolisers, so that molecular
genetics cannot at present replace the pharmacological
measure of debrisoquine metaboliser status.
We thank the clinicians of the Brompton Hospital, London, for
permission to study their patients. The debrisoquine assays were
performed by Dr Timothy P. Sloan, who was sadly lost in an
accident in 1983.
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